eFFECTOR Therapeutics, Inc. (EFTR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 26.33 Million USD | 4.6% |
| 2022 | 25.18 Million USD | -31.52% |
| 2021 | 36.77 Million USD | -75.31% |
| 2020 | 148.94 Million USD | 686.67% |
| 2019 | 18.93 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 26.3 Million USD | -0.13% |
| 2023 Q3 | 24.12 Million USD | -0.77% |
| 2023 Q1 | 26.74 Million USD | 6.2% |
| 2023 FY | 26.33 Million USD | 4.6% |
| 2023 Q2 | 24.31 Million USD | -9.08% |
| 2023 Q4 | 26.33 Million USD | 9.17% |
| 2022 FY | 25.18 Million USD | -31.52% |
| 2022 Q4 | 25.18 Million USD | 0.36% |
| 2022 Q3 | 25.09 Million USD | 5.21% |
| 2022 Q2 | 23.84 Million USD | -1.7% |
| 2022 Q1 | 24.26 Million USD | -34.02% |
| 2021 Q1 | 22.56 Million USD | -84.85% |
| 2021 FY | 36.77 Million USD | -75.31% |
| 2021 Q4 | 36.77 Million USD | -45.61% |
| 2021 Q3 | 67.6 Million USD | -57.29% |
| 2021 Q2 | 158.29 Million USD | 601.49% |
| 2020 Q1 | - USD | 0.0% |
| 2020 FY | 148.94 Million USD | 686.67% |
| 2020 Q4 | 148.94 Million USD | 0.0% |
| 2019 FY | 18.93 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -445.89% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -1008.544% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 32.337% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 80.142% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -847.787% |
| Better Therapeutics, Inc. | 23.84 Million USD | -10.473% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -217.95% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -164.071% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 17.129% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 62.066% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | -231.492% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 45.254% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 83.258% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -651.264% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -23.717% |
| Molecular Templates, Inc. | 31.17 Million USD | 15.502% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -110.461% |
| NexImmune, Inc. | 5.08 Million USD | -418.053% |
| Orgenesis Inc. | 35.53 Million USD | 25.879% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -59.514% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -9786.492% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -1047.503% |
| Scopus BioPharma Inc. | 7.45 Million USD | -253.333% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 94.674% |
| Statera Biopharma, Inc. | 22.67 Million USD | -16.151% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -141.332% |
| Trevena, Inc. | 48.26 Million USD | 45.425% |
| Vaxxinity, Inc. | 30.94 Million USD | 14.882% |
| Vaccinex, Inc. | 5.94 Million USD | -343.268% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -1238.135% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 31.361% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -853.773% |